EMEA-001943-PIP02-20-M01
Key facts
| Invented name |
Ultomiris
|
| Active substance |
ravulizumab
|
| Therapeutic area |
|
| Decision number |
P/0189/2022
|
| PIP number |
EMEA-001943-PIP02-20-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of patients with haematopoietic stem cell transplant associated thrombotic microangiopathy
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|